Edge Pharmaceuticals Limited Filleted accounts for Companies House (small and micro)

COMPANY REGISTRATION NUMBER: 10581135

Edge Pharmaceuticals Limited

Unaudited Financial Statements

30 June 2025

Edge Pharmaceuticals Limited

Director's Report

Year ended 30 June 2025

The director presents his report and the unaudited financial statements of the company for the year ended 30 June 2025 .

Director

The director who served the company during the year was as follows:

Mr G H Melamet

Small company provisions

This report has been prepared in accordance with the provisions applicable to companies entitled to the small companies exemption.

This report was approved by the board of directors on 23 June 2026 and signed on behalf of the board by:

Mr G H Melamet
Director

Registered office:

Unit 13, 2nd Floor

Olympia House

Armitage Road

London

NW11 8RQ

Edge Pharmaceuticals Limited

Statement of Income and Retained Earnings

Year ended 30 June 2025

		2025	2024
Note		EUR	EUR
Turnover	4	39,210	12,213

	--------	--------
Gross profit	39,210	12,213

Administrative expenses		14,038	4,413
		--------	--------
Operating profit	5	25,172	7,800

	--------	--------
Profit before taxation	25,172	7,800

Tax on profit	6	–	1,482
		--------	-------
Profit for the financial year and total comprehensive income		25,172	6,318
		--------	-------

All the activities of the company are from continuing operations.

Edge Pharmaceuticals Limited

Statement of Financial Position

30 June 2025

	2025	2024
Note	EUR	EUR

Current assets

Debtors	7	165,634	167,045
Cash at bank and in hand		71,624	47,128
		---------	---------
		237,258	214,173

Creditors: amounts falling due within one year	8	443,161	445,249
		---------	---------
Net current liabilities		205,903	231,076
		---------	---------
Total assets less current liabilities		( 205,903)	( 231,076)
		---------	---------
Net liabilities		( 205,903)	( 231,076)
		---------	---------

Capital and reserves

Called up share capital	9	2	2
Profit and loss account		( 205,905)	( 231,078)
		---------	---------
Shareholders deficit		( 205,903)	( 231,076)
		---------	---------

For the year ending 30 June 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Director's responsibilities:

- The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476 ;

- The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements .

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime.

These financial statements were approved by the board of directors and authorised for issue on 23 June 2026 , and are signed on behalf of the board by:

Mr G H Melamet
Director

Company registration number: 10581135

Edge Pharmaceuticals Limited

Statement of Cash Flows

Year ended 30 June 2025

	2025	2024
	EUR	EUR

Cash flows from operating activities

Profit for the financial year	25,172	6,318

Adjustments for:
Tax on profit	–	1,482
Accrued (income)/expenses	( 3,982)	256

Changes in:
Trade and other debtors	1,411	( 1,411)
Trade and other creditors	1,894	( 2,122)
	--------	-------
Cash generated from operations	24,495	4,523

Tax paid	–	( 1,482)
	--------	-------
Net cash from operating activities	24,495	3,041
	--------	-------

Net increase in cash and cash equivalents	24,495	3,041
Cash and cash equivalents at beginning of year	47,128	44,087
	--------	--------
Cash and cash equivalents at end of year	71,623	47,128
	--------	--------

Edge Pharmaceuticals Limited

Notes to the Financial Statements

Year ended 30 June 2025

1. General information

The company is a private company limited by shares, registered in England and Wales. The address of the registered office is Unit 13, 2nd Floor, Olympia House, Armitage Road, London, NW11 8RQ.

2. Statement of compliance

These financial statements have been prepared in compliance with FRS 102, 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland'.

3. Accounting policies

Basis of preparation

The financial statements have been prepared on the historical cost basis, as modified by the revaluation of certain financial assets and liabilities and investment properties measured at fair value through profit or loss.

The financial statements are prepared in sterling, which is the functional currency of the entity.

Revenue recognition

Turnover is measured at the fair value of the consideration received or receivable for goods supplied and services rendered, net of discounts and Value Added Tax. Revenue from the sale of goods is recognised when the significant risks and rewards of ownership have transferred to the buyer (usually on despatch of the goods); the amount of revenue can be measured reliably; it is probable that the associated economic benefits will flow to the entity; and the costs incurred or to be incurred in respect of the transactions can be measured reliably.

Income tax

The taxation expense represents the aggregate amount of current and deferred tax recognised in the reporting period. Tax is recognised in profit or loss, except to the extent that it relates to items recognised in other comprehensive income or directly in equity. In this case, tax is recognised in other comprehensive income or directly in equity, respectively. Current tax is recognised on taxable profit for the current and past periods. Current tax is measured at the amounts of tax expected to pay or recover using the tax rates and laws that have been enacted or substantively enacted at the reporting date.

Deferred tax is recognised in respect of all timing differences at the reporting date. Unrelieved tax losses and other deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date that are expected to apply to the reversal of the timing difference.

Foreign currencies

Foreign currency transactions are initially recorded in the functional currency, by applying the spot exchange rate as at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are translated at the exchange rate ruling at the reporting date, with any gains or losses being taken to the profit and loss account.

Financial instruments

A financial asset or a financial liability is recognised only when the company becomes a party to the contractual provisions of the instrument. Basic financial instruments are initially recognised at the transaction price, unless the arrangement constitutes a financing transaction, where it is recognised at the present value of the future payments discounted at a market rate of interest for a similar debt instrument. Debt instruments are subsequently measured at amortised cost. Where investments in non-convertible preference shares and non-puttable ordinary shares or preference shares are publicly traded or their fair value can otherwise be measured reliably, the investment is subsequently measured at fair value with changes in fair value recognised in profit or loss. All other such investments are subsequently measured at cost less impairment. Other financial instruments, including derivatives, are initially recognised at fair value, unless payment for an asset is deferred beyond normal business terms or financed at a rate of interest that is not a market rate, in which case the asset is measured at the present value of the future payments discounted at a market rate of interest for a similar debt instrument. Other financial instruments are subsequently measured at fair value, with any changes recognised in profit or loss, with the exception of hedging instruments in a designated hedging relationship.

Financial assets that are measured at cost or amortised cost are reviewed for objective evidence of impairment at the end of each reporting date. If there is objective evidence of impairment, an impairment loss is recognised in profit or loss immediately. For all equity instruments regardless of significance, and other financial assets that are individually significant, these are assessed individually for impairment. Other financial assets are either assessed individually or grouped on the basis of similar credit risk characteristics. Any reversals of impairment are recognised in profit or loss immediately, to the extent that the reversal does not result in a carrying amount of the financial asset that exceeds what the carrying amount would have been had the impairment not previously been recognised.

4. Turnover

The whole of the turnover is attributable to the principal activity of the company wholly undertaken in the United Kingdom.

5. Operating profit

Operating profit or loss is stated after charging/crediting:

	2025	2024
	EUR	EUR
Foreign exchange differences	4,408	( 11,876)
	-------	--------

6. Tax on profit

Major components of tax expense

	2025	2024
	EUR	EUR

Current tax:

UK current tax expense	–	1,482
	----	-------
Tax on profit	–	1,482
	----	-------

7. Debtors

	2025	2024
	EUR	EUR
Trade debtors	96,961	96,961
Other debtors	68,673	70,084
	---------	---------
	165,634	167,045
	---------	---------

8. Creditors: amounts falling due within one year

	2025	2024
	EUR	EUR
Trade creditors	440,661	438,767
Accruals and deferred income	2,500	6,482
	---------	---------
	443,161	445,249
	---------	---------

9. Called up share capital

Issued, called up and fully paid

	2025		2024
	No.	EUR	No.	EUR
Ordinary shares of EUR 2 each	1	2	1	2
	----	----	----	----

10. Analysis of changes in net debt

	At 1 Jul 2024	Cash flows	At 30 Jun 2025
	EUR	EUR	EUR
Cash at bank and in hand	47,128	24,496	71,624
	--------	--------	--------